How effective is psilocybin in treating conditions like PTSD and depression?
November 11, 2024
Psilocybin, a naturally occurring psychedelic compound, has garnered interest as a potential treatment for psychiatric conditions such as PTSD and depression. Various studies and reviews have investigated its efficacy and highlighted its therapeutic potential. Psilocybin-assisted therapy has shown significant, rapid, and sustained antidepressant effects in patients with major depressive disorder (MDD) and treatment-resistant depression (1, 7, 9, 14, 16, 27). Studies have typically involved controlled administration of psilocybin in therapeutic settings, leading to reductions in depression severity and improvement in quality of life (9, 10, 14, 17, 34). These benefits are often attributed to psilocybin's capacity to enhance emotional connectivity and acceptance, thereby facilitating psychological insights and emotional integration (13, 21, 29).
The therapeutic use of psilocybin for PTSD is also under consideration, with some promising results in clinical settings, although direct large-scale clinical evidence remains limited (3, 5, 18). Nonetheless, significant symptom reductions have been reported in small-scale and pilot studies, suggesting potential benefits for trauma-related disorders when combined with psychotherapy (19, 24, 33).
Despite these promising findings, the larger body of research remains nascent, and there are challenges related to understanding the precise mechanisms by which psilocybin exerts its effects. Studies suggest it might modulate neural plasticity, mediate emotional processing in the brain, and alter brain connectivity, which are crucial for its therapeutic efficacy (26, 31, 35). Patient accounts often emphasize the importance of structured therapeutic support, which enhances psilocybin's impact through guided introspection and integration (13, 29, 43).
Overall, psilocybin shows considerable promise for treating depression and seems potentially effective against PTSD, but further research is required. Focused efforts to delineate its mechanisms, long-term outcomes, and cross-condition applicability will be central to understanding and optimizing its therapeutic use (11, 21, 49). Continued regulatory scrutiny and controlled studies will be necessary to determine the safety and efficacy of these treatments at a larger scale (36, 42, 50).
References
1. Turkia, Mika. "Self-treatment of depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin—a retrospective case study." ResearchGate (2022).
2. Bird, Catherine IV, Nadav L. Modlin, and James JH Rucker. "Psilocybin and MDMA for the treatment of trauma-related psychopathology." International Review of Psychiatry 33.3 (2021): 229-249.
3. Khan, Amanda J., et al. "Psilocybin for trauma-related disorders." Disruptive Psychopharmacology (2022): 319-332.
4. Turkia, Mika. "Underground small-group therapy of treatment-resistant depression and complex post-traumatic stress disorder (C-PTSD) with psilocybin—A retrospective case study." (2022).
5. Varker, Tracey, et al. "Efficacy of psychoactive drugs for the treatment of posttraumatic stress disorder: a systematic review of MDMA, ketamine, LSD and psilocybin." Journal of psychoactive drugs 53.1 (2021): 85-95.
6. Choi, Charles, et al. "Mechanisms of psilocybin on the treatment of posttraumatic stress disorder." Journal of Psychopharmacology (2024): 02698811241286771.
7. Davis, Alan K., et al. "Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial." JAMA psychiatry 78.5 (2021): 481-489.
8. Turkia, Mika. "Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD—a retrospective case study." (2023).
9. Vargas, Ana Sofia, et al. "Psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases—a systematic review and meta-analysis of clinical trials." Biomedicines 8.9 (2020): 331.
10. Raison, Charles L., et al. "Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial." JAMA 330.9 (2023): 843-853.
11. Gyllvik, Sofia. "The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder." (2020).
12. Gomez, Liam Paul. "Tripping over Trauma: A proposal of psilocybin-assisted therapy for comorbid post-traumatic stress disorder and depression." (2022).
13. Crowe, Marie, et al. "Experiences of psilocybin treatment for clinical conditions: a qualitative metasynthesis." International journal of mental health nursing 32.4 (2023): 1025-1037.
14. Goodwin, Guy M., et al. "Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life." Journal of Affective Disorders 327 (2023): 120-127.
15. Gill, Hartej, et al. "The emerging role of psilocybin and MDMA in the treatment of mental illness." Expert Review of Neurotherapeutics 20.12 (2020): 1263-1273.
16. NGUYEN, ALICIA LILY. "How Psilocybin-Assisted Therapy May Serve as an Alternate Treatment to Improve Mental Health in Major Depressive Disorder (MDD)." (2023).
17. Gukasyan, Natalie, et al. "Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up." Journal of Psychopharmacology 36.2 (2022): 151-158.
18. Krediet, Erwin, et al. "Reviewing the potential of psychedelics for the treatment of PTSD." International Journal of Neuropsychopharmacology 23.6 (2020): 385-400.
19. Henner, Ryan L., Matcheri S. Keshavan, and Kevin P. Hill. "Review of potential psychedelic treatments for PTSD." Journal of the Neurological Sciences 439 (2022): 120302.
20. Watts, Rosalind, et al. "Patients’ accounts of increased connectedness and acceptance after psilocybin for treatment-resistant depression." Journal of humanistic psychology 57.5 (2017): 520-564.
21. Agin-Liebes, Gabrielle, and Alan K. Davis. "Psilocybin for the treatment of depression: a promising new pharmacotherapy approach." Disruptive Psychopharmacology (2021): 125-140.
22. Ross, Stephen, et al. "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial." Journal of psychopharmacology 30.12 (2016): 1165-1180.
23. Lowe, Henry, et al. "The therapeutic potential of psilocybin." Molecules 26.10 (2021): 2948.
24. Smith, F. L., J. C. Neill, and V. Wainwright. "An interpretative phenomenological analysis of the use of psilocybin by veterans with symptoms of trauma." Drug Science, Policy and Law 8 (2022): 20503245221124117.
25. Turkia, Mika. "Self-treatment of parental neglect-induced mixed anxiety and depressive disorder with psilocybin—a retrospective case study." (2023).
26. Mertens, Lea J., et al. "Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression." Journal of Psychopharmacology 34.2 (2020): 167-180.
27. Najib, Jadwiga. "The role of psilocybin in depressive disorders." Current Medical Research and Opinion 40.10 (2024): 1793-1808.
28. Kisely, Steve, et al. "A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders." Australian & New Zealand Journal of Psychiatry 57.3 (2023): 362-378.
29. Zeifman, Richard J., et al. "How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change." Journal of Affective Disorders 334 (2023): 100-112.
30. Reiff, Collin M., et al. "Psychedelics and psychedelic-assisted psychotherapy." American Journal of Psychiatry 177.5 (2020): 391-410.
31. Artin, Hewa, Sidney Zisook, and Dhakshin Ramanathan. "How do serotonergic psychedelics treat depression: The potential role of neuroplasticity." World Journal of Psychiatry 11.6 (2021): 201.
32. Averill, Lynnette A., and Chadi G. Abdallah. "Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine." Expert Opinion on Investigational Drugs 31.2 (2022): 133-137.
33. Agin-Liebes, Gabrielle, et al. "Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis." Journal of Humanistic Psychology 64.4 (2024): 564-591.
34. Griffiths, Roland R., et al. "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial." Journal of psychopharmacology 30.12 (2016): 1181-1197.
35. Vargas, Maxemiliano V., et al. "Psychedelics and other psychoplastogens for treating mental illness." Frontiers in psychiatry 12 (2021): 727117.
36. Nogrady, Bianca. "Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics." (2023).
37. Mohamed, Arafath, et al. "The efficacy of psychedelic-assisted therapy in managing post-traumatic stress disorder (PTSD): a new frontier?." Cureus 14.10 (2022).
38. Tullis, Paul. "How ecstasy and psilocybin are shaking up psychiatry." Nature 589.7843 (2021): 506-510.
39. Hodge, Andrew Troy, et al. "The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: a systematic review." Journal of psychoactive drugs 55.1 (2023): 40-50.
40. Rosenblat, Joshua D., et al. "Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin." Med 5.3 (2024): 190-200.
41. De Gregorio, Danilo, et al. "Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine." Journal of Neuroscience 41.5 (2021): 891-900.
42. Chi, Tingying, and Jessica A. Gold. "A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses." Journal of the Neurological Sciences 411 (2020).
43. Breeksema, Joost J., et al. "Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies." CNS drugs 34 (2020): 925-946.
44. Siegel, Ashley N., et al. "Registered clinical studies investigating psychedelic drugs for psychiatric disorders." Journal of Psychiatric Research 139 (2021): 71-81.
45. Davis, Alan K., et al. "Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD." BMJ open 13.5 (2023): e068884.
46. Belser, Alexander B., et al. "Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis." Journal of Humanistic Psychology 57.4 (2017): 354-388.
47. Modlin, Nadav Liam, et al. "Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions." Neuropsychiatric Disease and Treatment (2024): 109-135.
48. Davis, Alan K., et al. "Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans." Chronic Stress 4 (2020): 2470547020939564.
49. Barber, Gregory, Charles B. Nemeroff, and Steven Siegel. "A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability." American Journal of Psychiatry 179.12 (2022): 892-896.
50. Elsouri, Kawther N., et al. "Psychoactive drugs in the management of post traumatic stress disorder: A promising new horizon." Cureus 14.5 (2022).